Reduced noncovalent connections in leukoaraiosis

Expert Review of Neurotherapeutics

Volumn 8, Issue 2, 2008, Pages 205-213

  Szolnoki, Zoltán ^a  

^a Pandy Kalman County Hospital   (Hungary)

Author keywords

ATP; Dark cell phenomenon; Genetics; Kinesin; Leukoaraiosis; Network; Noncovalent connection; Water governed cycle; Weak chemical connections; White matter hyperintensity

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; CELL PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KINESIN; PHOSPHODIESTERASE V INHIBITOR;

BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN NERVE CELL; BRAIN TOXICITY; CHRONIC DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CYTOPLASM; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLIA CELL; HEREDITY; HISTOPATHOLOGY; HUMAN; LEUKOARAIOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DEPLETION; PROTEIN FOLDING; REVIEW; WHITE MATTER;

ANIMALS; HUMANS; LEUKOARAIOSIS; MODELS, BIOLOGICAL; NERVE NET; PROTEIN FOLDING; RISK FACTORS;

EID: 39549123233     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.2.205     Document Type: Review

References (81)

1. Hachinski VC, Potter P, Merskey H. Leuko-araiosis: an ancient term for a new problem. Can. J. Neurol. Sci. 13, 533-534 (1986). •• Summarizes the clinical aspects of leukoaraiosis.
2. Steingart A, Hachinski VC, Lau C et al. Cognitive and neurologic findings in subjects with diffuse white matter lucencies on computed tomographic scan (leukoaraiosis). Arch. Neurol. 44, 32-35 (1987).
3. Steingart A, Hachinski VC, Lau C et al. Cognitive and neurologic findings in demented patients with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis). Arch. Neurol. 44, 36-39 (1987).
4. Junque C, Pujol J, Vendrell P et al. Leukoaraiosis on magnetic resonance imaging and speed of mental processing. Arch. Neurol. 47, 151-156 (1990).
5. Liu CK, Miller BL, Cummings JL et al. A quantitative MRI study of vascular dementia. Neurology 42, 138-143 (1992).
6. Inzitari D, Simoni M, Pracucci G et al. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch. Intern. Med. 167, 81-88 (2007). •• Summarizes the clinical aspects of leukoaraiosis.
7. Ylikoski R, Ylikoski A, Erkinjuntti T et al. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch. Neurol. 50, 818-824 (1993).
8. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis, a review. Stroke 28, 652-659 (1997). •• Summarizes all clinical aspects of leukoaraiosis.
9. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc. Dis. 13(Suppl. 2), 7-14 (2002). • Clinical and pathological data of leukoaraiosis.
10. Pantoni L, Poggesi A, Basile AM et al. Leukoaraiosis predicts hidden global functioning impairment in nondisabled older people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. J. Am. Geriatr. Soc. 54, 95-101 (2006).
11. van Gijn J. Leukoaraiosis and vascular dementia. Neurology 51, 3-8 (1998). • Underpins the importance of vascular white mater damage.
12. Hassan A, Hunt BJ, O'Sullivan M et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 126, 424-432 (2003). • Postulates endothelial dysfunctions behind leukoaraiosis.
13. Wada M, Nagasawa H, Kurita K et al. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J. Neurol. Sci. 255, 27-34 (2007).
14. Hoth KF, Tate DF, Poppas A et al. Endothelial function and white matter hyperintensities in older adults with cardiovascular disease. Stroke 38, 308-312 (2007). •• Data provide evidence for the roles of endothelial dysfunctions in leukoaraiosis.
15. Clarke R, Joachim C, Esiri M et al. Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia. Ann. NY Acad. Sci. 903, 497-500 (2000). •• Data have confirmed the roles of homocysteine and folic acid in the development and progression of leukoaraiosis.
16. Wright CB, Paik MC, Brown TR et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 36, 1207-1211 (2005).
17. Pak KJ, Chan SL, Mattson MP. Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide. Neuromolecular Med. 3, 119-128 (2003).
18. Szolnoki Z. Chemical events behind leukoaraiosis: medicinal chemistry offers new insight into a specific microcirculation disturbance in the brain (a chemical approach to a frequent cerebral phenotype). Curr. Med. Chem. 14, 1027-1036 (2007). •• Setting out from chemical pathways, the article postulates that chronic shortage of oxygen may lead to the development of leukoaraiosis. This work bridges the physiological and chemical events and also offers therapeutic approaches to leukoaraiosis.
19. Szolnoki Z. Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis). Neuromolecular Med. 9, 21-34 (2007). •• Discusses the intracellular molecular events that may occur in leukoaraiosis. It likewise provides a new molecular approach to leukoaraiosis.
20. Brown WR, Moody DM, Thore CR et al. Vascular dementia in leukoaraiosis may be a consequence of capillary loss not only in the lesions, but in normal-appearing white matter and cortex as well. J. Neurol. Sci. 257, 62-66 (2007). •• Experimental observation underpins the theory on hypoxia in leukoaraiosis.
21. Yao H, Sadoshima S, Ibayashi S et al. Leukoaraiosis and dementia in hypertensive patients. Stroke 23, 1673-1677 (1992).
22. Amar K, Macgowan S, Wilcock G et al. Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. Int. J. Geriat. Psychiatry 13, 585-590 (1998).
23. Hassan A, Lansbury A, Catto AJ et al. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. J. Neurol. Neurosurg. Psychiatry 72, 343-346 (2002).
24. Sierra C, Coca A, Gómez-Angelats E et al. Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension. Hypertension 39, 343-347 (2002).
25. Szolnoki Z, Somogyvári F, Kondacs A et al. Evaluation of the roles of common genetic mutations in leukoaraiosis. Acta Neurol. Scand. 104, 281-287 (2001). •• Confirms the possible role of endothelial dysfunctions in leukoaraiosis from a genetic point of view.
26. Tian J, Shi J, Bailey K et al. A polymorphism in the angiotensin 1-converting enzyme gene is associated with damage to cerebral cortical white matter in Alzheimer's disease. Neurosci. Lett. 354, 103-106 (2004).
27. De Ciuceis C, Amiri F, Brassard P et al. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler. Thromb. Vasc. Biol. 25, 2106-2113 (2005).
28. Watanabe S, Tagawa T, Yamakawa K et al. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler. Thromb. Vasc. Biol. 25, 2376-2380 (2005).
29. Ginanneschi A, Marinoni M, Inzitari D et al. Blood pressure monitoring in patients with leukoaraiosis. Neurology 42(Suppl. 3), 273 (1992).
30. Harrison MJ, Marshall J. Hypoperfusion in the aetiology of subcortical arteriosclerotic encephalopathy (Binswanger type). J. Neurol. Neurosurg. Psychiatry 47, 754 (1984).
31. Matsushita K, Kuriyama Y, Nagatsuka K. Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension 23, 565-568 (1994).
32. McQuinn BA, O'Leary DH. White matter lucencies on computed tomography, subacute arteriosclerotic encephalopathy (Binswanger's disease), and blood pressure. Stroke 18, 900-905 (1987).
33. Shimada K, Kawamoto A, Matsubayashi K et al. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J. Hypertens. 10, 875-878 (1992).
34. Schmidt H, Fazekas F, Kostner GM et al. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke 32, 405-412 (2001).
35. Sachdev P, Parslow R, Salonikas C et al. Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch. Neurol. 61, 1369-1376 (2004).
36. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 338, 1042-1050 (1998).
37. Wen HM, Baum L, Cheung WS et al. Apolipoprotein E epsilon4 allele is associated with the volume of white matter changes in patients with lacunar infarcts. Eur. J. Neurol. 13, 1216-1220 (2006).
38. Persson J, Lind J, Larsson A et al. Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology 66, 1029-1033 (2006).
39. Lemmens R, Görner A, Schrooten M, Thijs V. Association of apolipoprotein E epsilon2 with white matter disease but not with microbleeds. Stroke 38, 1185-1188 (2007).
40. Bartzokis G, Lu PH, Geschwind DH et al. Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol. Psychiatry 62(12), 1380-1387 (2007).
41. Høgh P, Garde E, Mortensen EL et al. The apolipoprotein E epsilon4-allele and antihypertensive treatment are associated with increased risk of cerebral MRI white matter hyperintensities. Acta. Neurol. Scand. 115, 248-253 (2007).
42. Szolnoki Z, Somogyvári F, Kondacs A et al. Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoaraiosis. Acta. Neurol. Scand. 109, 222-227 (2004).
43. Schmidt R, Schmidt H, Fazekas F et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphism: three-year follow-up of the Austrian Stroke Prevention Study. Arterioscler. Thromb. Vasc. Biol. 20, 1811-1816 (2000).
44. Fornage M, Mosley TH, Jack CR et al. Family-based association study of matrix metalloproteinase-3 and -9 haplotypes with susceptibility to ischemic white matter injury. Hum. Genet. 120, 671-680 (2007). •• Experimental genetic data have proven the importance of the intact BBB in the white matter of the brain.
45. Szolnoki Z, Kondacs A, Mandi Y, Somogyvari F. A genetic variant in cytoskeleton motors amplifies susceptibility to leukoaraiosis in hypertensive smokers: gene-environmental interactions behind vascular white matter demyelinization. J. Mol. Neurosci. 33, 173-179 (2007). •• Clinical and genetic data have confirmed the role of malfunction of the cytoskeleton in leukoaraiosis.
46. Szolnoki Z. Genetic variant-associated endothelial dysfunction behind small-vessel cerebral circulatory disorders: a new pathomechanism behind common cerebral phenotypes. Mini Rev. Med. Chem. 7, 527-530 (2007). •• Summarizes the genetic data of vascular white matter damage.
47. Szolnoki Z. A dynamically changing intracellular water network serves as a universal regulator of the cell: the water-governed cycle. Biochem. Biophys. Res. Commun. 357, 331-334 (2007). •• Suggests a new general enzyme regulation cycle in living cells. This biochemical system theory may provide an explanation for cytoskeleton involvement in leukoaraiosis.
48. Csordas A, Mazlo M, Gallyas F. Recovery versus death of "dark" (compacted) neurons in a nonimpaired parenchymal environment: light and electron microscopic observation. Acta Neuropathol. (Berl.) 106, 37-49 (2003).
49. Gallyas F, Farkas O, Mazlo M. Gel-to-gel phase transition may occur in mammalian cells: mechanism of formation of "dark" (compacted) neurons. Biol. Cell. 96, 313-324 (2004). •• Offers new approaches to the dark neuron phenomenon.
50. Gallyas F, Gasz B, Szigeti A, Mazlo M. Pathological circumstances impair the ability of "dark" neurons to undergo spontaneous recovery. Brain Res. 1110, 211-220 (2006).
51. Zsombok A, Toth Z, Gallyas F. Basophilia, acidophilia and argyrophilia of "dark" (compacted) neurons during their formation, recovery or death in an otherwise undamaged environment. J. Neurosci. Methods 142, 145-152 (2005).
52. Csermely P. Strong links are important but weak links stabilize them. Trends Biochem. Sci. 29, 331-334 (2004). •• Renders a complex system theory in biology.
53. Otzen DE, Oliveberg M. Salt-induced detour through compact regions of the protein folding landscape. Proc. Natl Acad. Sci. USA 96, 11746-11751 (1999).
54. Csermely P. Water and cellular folding processes. Cell. Mol. Biol. 47, 797-800 (2001).
55. Doye JP. The network topology of a potential energy landscape: a static scalefree network. Phys. Rev. Lett. 88, 238701 (2002). •• Demonstrates the roles of water in cellular protein folding processes.
56. Plotkin SS, Wolynes PG. Buffered energy landscapes: another solution to the kinetic paradoxes of protein folding. Proc. Natl Acad. Sci. USA 100, 4417-4422 (2003).
57. Barron LD, Hecht L, Wilson G. The lubricant life: a proposal that solvent water promotes extremely fast conformational fluctuations in mobile heteropolypeptide structure. Biochemistry 36, 13143-13147 (1997).
58. Levy Y, Onuchic JN. Water and proteins: a love-hate relationship. Proc. Natl Acad. Sci. USA 101, 3325-3326 (2004). •• Illustrates the love-hate relationship between the water and proteins.
59. Papoian GA, Ulander J, Eastwood MP et al. Water in protein structure prediction. Proc. Natl Acad. Sci. USA 101, 3352-3357 (2004).
60. Rao F, Caflisch A. The protein folding network. J. Mol. Biol. 342, 299-306 (2004).
61. Klibanov AM. What is remembered and why? Nature 374(6523), 596 (1995).
62. Lehninger AL. Glycolysis. In: Biochemistry. Lehninger AL (Ed.). Worth Publisher Inc., NY, USA 417-443 (1975).
63. Lehninger AL. Oxidative phosphorylation, mitochondrial structure and the compartmentation of respiratory metabolism. In: Biochemistry. Lehninger AL (Ed.). Worth Publisher Inc., NY, USA 509-542 (1975).
64. Ravasz E, Somera AL, Mongru DA et al. Hierarchical organization of modularity in metabolic network. Science 297, 1551-1555 (2002).
65. Feynman RP, Leighton RB, Sands M. Section 21.9. In: The Feynman Lectures on Physics. Volume 3. Quantum Mechanics. Addison-Wesley Professional, Boston, MA, USA (1965).
66. Winfree AT. Biological rhythms and behaviour of populations of coupled oscillators J. Theor. Biol. 16, 15-42 (1967).
67. Lindner JF. Meadows BK, Ditto WL. Array enhanced stochastic resonance and spatiotemporal synchronization. Phys. Rev. Lett. 75, 3-6 (1995).
68. Bressloff PC, Coombes S. Travelling waves in a chain of pulse-coupled oscillators. Phys. Rev. Lett. 80, 4815-4818 (1998).
69. Blasius B, Huppert A, Stone L. Complex dynamics and phase synchronization in spatially extended ecological systems. Nature 399, 354-359 (1999).
70. Gao Z, Hu B, Hu G. Stochastic resonance of small-world networks. Phys. Rev. E65, 016209 (2001).
71. Ponzi A, Aizawa Y. Criticality and punctuated equilibrium in a spin system model of a financial market. Chaos Solution Fractals 11, 1739-1746 (2002).
72. Derenyi I, Farkas I, Palla G, Vicsek T. Topological phase transitions of random networks. Physica A 334, 583-590 (2004).
73. Palla G, Derenyi I, Farkas I, Vicsek T. Statistical mechanics of topological phase transitions in networks. Phys. Rev. E69, 046117 (2004).
74. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 411, 41-42 (2001).
75. Soti C, Sreedhar AS, Csermely P. Apoptosis, necrosis and cellular senescence: chaperone occupancy as a potential switch. Aging Cell 2, 39-45 (2003).
76. Kenworthy AK, Nichols BJ, Remmert CL et al. Dymamics of putative raft-associated proteins at the cell surface. J. Cell. Biol. 165, 735-746 (2004).
77. Abe K, Aoki M, Kawagoe J et al. Ischemic delayed neuronal death. A mitochondrial hypothesis. Stroke 26, 1478-1489 (1995). •• Discusses the intracellular molecular events behind neuronal death. It also suggests new approaches to the delayed neuronal death.
78. Gallyas F, Zoltay G, Dames W. Formation of "dark" (argyrophilic) neurons of various origins proceeds with a common mechanism of biophysical nature (a novel hypothesis). Acta Neuropathol. (Berl.) 83, 4-9 (1992). •• New approach to the dark neuron phenomenon.
79. Gallyas F, Zoltay G, Horvath Z et al. An immediate morphopathologic response of neurons to electroshock; a reliable model for producing "dark" neurons in experimental neuropathology. Neurobiology (Bp.) 1, 133-146 (1993). •• New approach to the dark neuron phenomenon.
80. Sawada H, Udaka F, Izumi Y et al. Cerebral white matter lesions are not associated with ApoE genotype but with age and female sex in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 68, 653-666 (2000).
81. Schmidt R, Schmidt H, Fazekas F et al. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 28, 951-956 (1997).